Low-dose triple combination of inhibitors reduced kinase activity in both PI3K/AKT/mTOR and mitogen-activated protein kinase pathways, inhibited proliferation in vitro, and significantly reduced tumor growth in PDX models, suggesting this combination merits further clinical exploration[124]. This evidence concerns the gene PIK3CB and neoplasm.